IMR Press / RCM / Volume 22 / Issue 3 / DOI: 10.31083/j.rcm2203093
Open Access Systematic Review
Effects of alirocumab on cardiovascular events and all-cause mortality: a systematic review and meta-analysis
Show Less
1 General Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, 110042 Shenyang, Liaoning, China
2 Hepatobiliary Pancreatic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, 110042 Shenyang, Liaoning, China

Academic Editor: Takatoshi Kasai

Rev. Cardiovasc. Med. 2021, 22(3), 873–881; https://doi.org/10.31083/j.rcm2203093
Submitted: 6 July 2021 | Revised: 26 July 2021 | Accepted: 13 August 2021 | Published: 24 September 2021
(This article belongs to the Special Issue State-of-the-Art Cardiovascular Medicine in Asia 2021)
Copyright: © 2021 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Abstract

Evaluation of the effects of alirocumab on cardiovascular (CV) events, CV mortality and all-cause mortality. Data search was carried out using the Cochrane Library, PubMed, Web of Science and Embase. The search time is up to November 18, 2020. All randomized clinical trials (AEs) comparing alirocumab with placebo were searched. Meta-analysis was performed by Review Manager version 5.3 (The Cochrane Collaboration, Copenhagen, Denmark), and the heterogeneity between studies was tested by Cochrane’s Q test and measured with I2 statistics. A total of 13 randomized controlled trials with 24,815 participants were included. Alirocumab usage can considerably lower the incidence of CV events when compared to the control group (risk ratio(RR) 0.89, 95% confidence interval(CI) 0.83–0.95). No significant difference in CV mortality between the two groups was observed (RR 0.87, 95% CI 0.74–1.04). Treatment with alirocumab has been associated with a major decrease in all-cause mortality compared to placebo (RR 0.80, 95% CI 0.66–0.96). The incidence of serious adverse events (AEs) was similar in the two groups (RR 0.94, 95% CI 0.90–0.99). Alirocumab can reduce CV events and all-cause mortality. The AEs were mild and tolerable.

Keywords
Alirocumab
CV events
All-cause mortality
Meta-analysis
Figures
Fig. 1.
Share
Back to top